Market CompetitionThough KT-621 shows promise, it faces competition from existing treatments like Dupixent, which may impact its market penetration.
Product Development RisksThe decision to advance next-gen IRAK4 degrader, KT-485, is seen as a long-term positive, allowing the development of a molecule with greater selectivity and potency, but may involve significant development challenges.